| First Author | Zerafa N | Year | 2005 |
| Journal | J Immunol | Volume | 175 |
| Issue | 9 | Pages | 5586-90 |
| PubMed ID | 16237043 | Mgi Jnum | J:103779 |
| Mgi Id | MGI:3610713 | Doi | 10.4049/jimmunol.175.9.5586 |
| Citation | Zerafa N, et al. (2005) Cutting edge: TRAIL deficiency accelerates hematological malignancies. J Immunol 175(9):5586-90 |
| abstractText | TNF apoptosis-inducing ligand is attracting considerable interest as a potential extrinsic tumor suppressor mechanism, although previous reports have conveyed somewhat contrasting views regarding the likely importance of this pathway. In this study, we provide the first evaluation of spontaneous tumor formation over the life span of TRAIL-deficient mice. Interestingly, >25% of these mice do develop lymphoid malignancies after 500 days of life. TRAIL suppressed the initiation and development of both tumors of lymphoid and stromal origin in the context of the loss of at least one p53 allele. Specific examination of the role of TRAIL in Her2/neu oncogene-driven mammary epithelial cancer revealed no critical role for TRAIL despite the inherent TRAIL sensitivity of such mammary carcinomas. Overall, the data indicate an important function of TRAIL in controlling carcinogenesis, but suggest that further examination of this pathway in epithelial malignancies is warranted. |
